February 2018

Chembio Diagnostics Completes Public Offering

North America - United States | North America | United States - Minnesota

Chembio Diagnostic develops, manufactures and commercializes point-of-care diagnostic tests that are used to detect or monitor diseases. All products that are currently being developed are based on the company’s patented DPP® technology, which is a novel point-of-care diagnostic platform that offers certain customer advantages, as compared to traditional lateral flow technology. Our firm represented Craig-Hallum Capital Group LLC as the sole underwriter for the $12 million offering.

Related Legal Services

The Faegre Baker Daniels website uses cookies to make your browsing experience as useful as possible. In order to have the full site experience, keep cookies enabled on your web browser. By browsing our site with cookies enabled, you are agreeing to their use. Review Faegre Baker Daniels' cookies information for more details.